Kiora Pharmaceuticals, Inc
Kiora Pharmaceuticals Inc. is a U.S.-based specialty clinical-stage ophthalmology company developing small-molecule therapies for retinal and inflammatory eye diseases. Its pipeline centers on KIO-301, KIO-104 and KIO-101, with the company still in development mode and reliant on external financing and partnering to advance programs toward commercialization.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaA vision-restoring small molecule photoswitch being developed for late-stage retinal degenerative diseases.
An intravitreal DHODH inhibitor in clinical development for retinal inflammatory diseases.
A topical eye-drop formulation of the KIO-104 molecule being positioned for partnership.
Upfront and milestone-related revenue from partnering agreements such as the TOI license.
Asiakkaat
Kiora does not sell commercial products broadly today; its current counterparties are pharmaceutical partners, clinical investigators, and eventually ophthalmologists and specialty eye-care providers if products are approved. The company’s near-term economic model depends on licensing and collaboration partners, while the eventual end users are patients with rare or inflammatory retinal diseases treated through specialist channels.
Buy rights to KIO-301/KIO-101 or other assets to fund development and access the science.
Investigators, hospitals and research centers that enroll patients and generate clinical data.
Would prescribe KIO-301 if approved for inherited retinal degeneration.
Would use KIO-104 for retinal inflammatory indications if approved.
End users of the therapies, especially those with limited treatment options.
Strategia
Kiora’s strategy is to advance a small number of ophthalmology assets through clinical proof-of-concept while using partnerships to reduce capital intensity. The company is also prioritizing financing flexibility, since continued development depends on equity, debt, grants and collaboration proceeds.
KIO-301 is the most differentiated asset and could address unmet need in inherited retinal disease.
Clinical validation in retinal inflammation is needed to support partnering or future commercialization.
The company has paused internal development and wants a partner to fund further work.
The company needs capital to continue operations and avoid delaying or terminating programs.
Maantiede
Kiora is headquartered in the United States and its development programs are intended for major regulated markets including the U.S., Europe and other large regions. The company’s geography is therefore driven less by current sales footprint and more by where it can run clinical trials, secure regulatory approval, and sign partnering agreements.
Riskit
Kiora is a development-stage biotech with no meaningful commercial revenue, so its business depends on successful clinical outcomes, regulatory approvals and access to capital. The main risks are funding shortfalls, trial or regulatory setbacks, and the possibility that partnering terms force the company to give up economics or control over key assets.
The company needs additional capital to fund operations and development, and may not obtain it on acceptable terms.
Pipeline value depends on positive efficacy and safety data in small, specialized ophthalmic indications.
Even promising data may not translate into approvable endpoints or market authorization.
The company has a history of losses and negative cash flows, increasing sensitivity to spending changes.
Kohdistuu: Operating expenses and runway
To raise funds, Kiora may need to license assets on terms that reduce future upside.
Kirjanpito
Harkinnanvaraiset erätThe January 2024 TOI agreement generated $16 million of collaboration revenue from an upfront payment.
Vaikutus: Revenue timing can be lumpy and driven by contract terms rather than product sales
Trial costs are accrued based on progress, patient enrollment and vendor invoices that may arrive later.
Vaikutus: Quarterly operating expense volatility
The company discloses dependence on future financing and uncertainty around continued operations.
Vaikutus: Material for liquidity and valuation analysis
As a development-stage biotech, equity awards can be an important part of employee compensation.
Vaikutus: Affects operating loss and non-cash expense
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
KALA BIO, Inc
KALA · Pharmaceutical Preparations
Kodiak Sciences Inc.
KOD · Biological Products, (No Diagnostic Substances)
Keros Therapeutics, Inc.
KROS · Pharmaceutical Preparations
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling.
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
Päivitetty: 24.9.2026